Literature DB >> 36069910

[Osteonecrosis-severe side effect of treatment for acute lymphoblastic leukemia].

Michaela Kuhlen1, Marina Kunstreich2, Nicola Gökbuget3, Gabriele Escherich4.   

Abstract

Osteonecrosis occurs as an acute and long-term serious side effect in children, adolescents, and adults with acute lymphoblastic leukemia. It is associated with severe pain and reduced mobility, ultimately leading to joint destruction and significant long-term morbidity. The cumulative incidence ranges from 11 to 20% in adolescents and young adults. In symptomatic patients, multiple joints are frequently affected, which in turns poses a risk factor for the development of severe osteonecrosis. The genesis of leukemia-associated osteonecrosis is multifactorial. Risk factors include the use of corticosteroids and asparaginase. These exert their effects on the blood supply to the bone through hypercholesterolemia, hypertriglyceridemia, and hypertension. Bacteriemia, genetic susceptibility, and stem cell transplantation pose additional risk factors. The treatment of osteonecrosis is challenging and not evidence based. Preventive measurements have as yet mainly been tested in preclinical models.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Adolescents; Bone necrosis; Children; Quality of life; Risk factors

Mesh:

Substances:

Year:  2022        PMID: 36069910     DOI: 10.1007/s00132-022-04301-1

Source DB:  PubMed          Journal:  Orthopadie (Heidelb)        ISSN: 2731-7145


  58 in total

Review 1.  Pathophysiology and natural history of avascular necrosis of bone.

Authors:  Pierre Lafforgue
Journal:  Joint Bone Spine       Date:  2006-08-08       Impact factor: 4.929

Review 2.  Osteonecrosis in children with acute lymphoblastic leukemia.

Authors:  Marina Kunstreich; Sebastian Kummer; Hans-Juergen Laws; Arndt Borkhardt; Michaela Kuhlen
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

3.  Bony morbidity in children treated for acute lymphoblastic leukemia.

Authors:  A J Strauss; J T Su; V M Dalton; R D Gelber; S E Sallan; L B Silverman
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

Review 4.  Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis.

Authors:  Christian Powell; Christopher Chang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

5.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.

Authors:  L A Mattano; H N Sather; M E Trigg; J B Nachman
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

Review 6.  Skeletal Morbidity in Children and Adolescents during and following Cancer Therapy.

Authors:  Sogol Mostoufi-Moab; Leanne M Ward
Journal:  Horm Res Paediatr       Date:  2018-11-27       Impact factor: 2.852

7.  Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.

Authors:  Laura J Janke; Chengcheng Liu; Peter Vogel; Jitesh Kawedia; Kelli L Boyd; Amy J Funk; Mary V Relling
Journal:  Am J Pathol       Date:  2013-05-11       Impact factor: 4.307

Review 8.  Osteonecrosis in children and adolescents with cancer.

Authors:  Ronald D Barr; Alessandra Sala
Journal:  Pediatr Blood Cancer       Date:  2008-02       Impact factor: 3.167

Review 9.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia
Journal:  Blood       Date:  2008-03-11       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.